People · Operator
Named in public records as an officer, director or promoter · active 2022–2024 · Biotech / Pharma, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Akers Biosciences, Inc. | — | Biotech / Pharma | Series B | $78.7M | $30.5M | 2022 |
| Telomir Pharmaceuticals, Inc. | — | Pharmaceuticals | Pre-Seed | $1.0M | $9.7M | 2023 |
Chris Chapman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Chris Chapman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Craig Eagle | 2 | 4 |
| Jude Uzonwanne | 2 | 3 |
| Joshua Silverman | 1 | 8 |
| Bill White | 1 | 5 |
| Bruce Bernstein | 1 | 5 |
| Robert C. Schroeder | 1 | 4 |
| JAMES MCNULTY | 1 | 3 |
| Stuart Benson | 1 | 2 |
| David Vorhoff | 1 | 2 |
| Joshua C. Silverman | 1 | 2 |
| Thomas Knox | 1 | 2 |
| Brandon Knox | 1 | 1 |
| Raza E. Bokhari | 1 | 1 |
| John Gormally | 1 | 1 |
| Gary Rauch | 1 | 1 |
| Robert E. Andrews | 1 | 1 |
| Tuck Talhia | 1 | 1 |
| Hugh McColl | 1 | 1 |
| Christopher Schreiber | 1 | 1 |
| Ian Rhodes | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.